The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to ...

At Novartis’s manufacturing sites for tisagenlecleucel, they maintain an illuminated ‘wall of hope’; for every patient batch they manufacture, they turn on one additional light as a symbol ...

Novartis hopes of improving on tacrolimus as the standard drug for preventing organ rejection in transplant patients have been dashed after its iscalimab candidate failed a mid-phase trial. An ...